Vaxcyte, Inc. (PCVX) awards 23,029 stock options to director John Markels
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vaxcyte, Inc. director John Markels reported a compensatory grant of 23,029 stock options, each exercisable for one share of common stock at an exercise price of $56.04 per share. The options expire on July 16, 2036 and vest over 36 months: one-third vests on July 16, 2027, and the remaining portion vests in equal monthly installments thereafter, subject to his continuous service. Following this award, he holds 23,029 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Markels John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 23,029 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 23,029 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 23,029 options
Exercise price: $56.04 per share
Expiration date: July 16, 2036
+2 more
5 metrics
Stock options granted
23,029 options
Grant of stock options to director John Markels
Exercise price
$56.04 per share
Exercise price for the stock options granted on July 16, 2026
Expiration date
July 16, 2036
Expiration of the granted stock options
Total derivative securities after grant
23,029 options
Director’s holdings following the reported transaction
Vesting period
36 months
Options vest over 36 months, starting July 16, 2027
Key Terms
Stock Option (right to buy), exercise price, vesting, continuous service
4 terms
Stock Option (right to buy) financial
"security_title is listed as Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price is shown as 56.0400 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"Option shall vest over 36 months, 1/3 of which will vest on July 16, 2027"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service other
"subject to Reporting Person's continuous service to the Company"
FAQ
What insider equity award did Vaxcyte (PCVX) director John Markels receive?
Director John Markels received a grant of 23,029 stock options in Vaxcyte, Inc. Each option is exercisable for one share of common stock at an exercise price of $56.04, with vesting over 36 months and expiration on July 16, 2036.
What is the exercise price of the new Vaxcyte (PCVX) stock options granted to John Markels?
The new stock options granted to John Markels have an exercise price of $56.04 per share. They are options to purchase Vaxcyte common stock, vesting over 36 months and expiring on July 16, 2036, subject to his continuous service with the company.
How do the Vaxcyte (PCVX) options granted to John Markels vest over time?
The options vest over 36 months: one-third of the grant vests on July 16, 2027, and 1/36 of the total vests monthly thereafter. All vesting is conditioned on John Markels’ continuous service to Vaxcyte through each vesting date.
When do the newly granted Vaxcyte (PCVX) stock options to John Markels expire?
The newly granted stock options to John Markels expire on July 16, 2036. After that date, any unexercised options become worthless. Until expiration, he may exercise vested options at the $56.04 exercise price, subject to plan and service conditions.
Is the Vaxcyte (PCVX) Form 4 for John Markels an open-market stock purchase?
No. The Form 4 reports a grant/award acquisition of stock options, not an open-market share purchase. Markels received 23,029 options at a $56.04 exercise price as compensation, with vesting tied to his ongoing service at Vaxcyte.